Testing a new drug to preserve insulin production in type 1 diabetes
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study tests a new drug called SAB-142, which aims to stop the immune system from attacking insulin-making cells in type 1 diabetes. It may help preserve your body's ability to make insulin. The trial will check if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 15 and 40 years old (or 5 to 40 for part B) and weigh at least 16 kg.
- You must have been diagnosed with type 1 diabetes within the last 100 days.
- You must test positive for at least one diabetes-related autoantibody (GAD65, IA-2, ZnT8, or insulin).
- You must not have certain medical conditions like active infections, liver problems, blood count abnormalities, or recent use of immune-altering drugs.
- Women must not be pregnant or breastfeeding and must use contraception if applicable.
- You must be willing to follow the study schedule and avoid other experimental treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two different medications (Anti-Thymocyte Globulin and Adalimumab or Verapamil) to see if they can slow down the loss of insulin production in people with newly diagnosed type 1 diabetes. Participants will be randomly assigned to receive one of the treatments and will be followed for about a year to see how well their bodies still make insulin.
This study tests if denosumab, a drug normally used for bone health, can help preserve your body's own insulin production in type 1 diabetes. It might slow the loss of insulin-making cells, helping you maintain better blood sugar control over time.
This trial tests a new drug called IMC-S118AI in people with type 1 diabetes. The goal is to see if it can help preserve the remaining function of insulin-making cells in the pancreas, which are important for controlling blood sugar.
This Phase 1/2 study tests whether CELZ-201 is safe and can help the body keep making some of its own insulin in people who were recently diagnosed with type 1 diabetes. You may be eligible if your diabetes started within the past year and your tests show you still have some insulin-making activity.
This study tests a system that measures blood sugar and automatically adjusts insulin delivery. It is for adults with type 1 diabetes who use insulin injections or a pump.
This trial tests a new way to give a medicine called anti-thymocyte globulin (ATG) with or without verapamil, a blood pressure drug. It aims to slow down the loss of insulin-making cells in people newly diagnosed with type 1 diabetes.
Hear when a new Type 1 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.